SPDR S&P Biotech ETF
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
26.24% more ownership
Funds ownership: 129.8% [Q3] → 156.05% (+26.24%) [Q4]
4% less capital invested
Capital invested by funds: $10.2B [Q3] → $9.8B (-$357M) [Q4]
5% less funds holding
Funds holding: 759 [Q3] → 723 (-36) [Q4]
14% less first-time investments, than exits
New positions opened: 100 | Existing positions closed: 116
29% less funds holding in top 10
Funds holding in top 10: 21 [Q3] → 15 (-6) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 278
38% less call options, than puts
Call options by funds: $2.07B | Put options by funds: $3.32B
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Based on 6 articles about XBI published over the past 30 days
Negative
CNBC Television
1 week ago
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
Neutral
CNBC Television
1 week ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Neutral
Zacks Investment Research
1 week ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.
Negative
CNBC Television
3 weeks ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Negative
New York Post
3 weeks ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Neutral
CNBC Television
3 weeks ago
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Neutral
CNBC Television
1 month ago
Single stock picking is the only way to make money in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Neutral
CNBC Television
1 month ago
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Neutral
Zacks Investment Research
1 month ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Positive
Seeking Alpha
1 month ago
Invest In A New Biotech Bull Market With XBI And IBB
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides more leverage to the biotech turnaround trade. Falling interest rates, weak GDP growth, low inflation, and Fed rate cuts mean the macro environment is ripe for biotech.
Charts implemented using Lightweight Charts™